Our story
Revolutionizing Diagnostics with AI
In 2016, a groundbreaking discovery revealed that dogs could detect cancer in human urine [1]. This remarkable ability sparked a bold idea—what if we could harness the power of AI to replicate and scale what dogs do naturally? That question became the foundation of Luventix.
At Luventix, we believe diagnosis is the gateway to better health. Yet, millions worldwide suffer from undiagnosed but treatable conditions because traditional diagnostics are expensive, slow, and require specialized equipment and personnel. We set out to change that.
Our innovative urine-based technology has the potential to evaluate multiple diseases from a single sample, paving the way for more affordable and accessible screening worldwide. Powered by mechanistic AI modeling, our approach has the potential to accelerate discovery and reduce research and development timelines by as much as a decade.
We’re not just developing diagnostics; we’re transforming the future of healthcare— one sample at a time.
Luventix validates Model for Colon Cancer with AUC = 0.978
Vern Norviel joins Luventix Advisory Board
Read more >
Luventix to present at LD Micro Main Event XVII Conference
Read more >
Luventix obtains IRB approval for observational study protocol covering Colon Cancer, Crohn's and Celiac Disease and SIBO
Veterinary License launches Beta test of HSA withAUC = 0.9
Luventix adds four industry luminaries to advisory board: Dr. David Wishard, Dr. Oliver Fiehn, Prof. Allan Hackshaw, Dominic Marasco
Closed $1M on Safe note with $10M Cap and 15% Discount
Filed 97 Claim Patent to protect technology
12 Modelling studies completed using 3rd party data with samples ranging from 30-1,200 with performance consistent with 2018 Tallahassee Study
Luventix Inc. founded by Martin Martinov, Dejan Nenov and George Holmes
Clinic in Tallahassee conducts two studies under IRB control to initially validate modelling techniques for modelling disease
>95% Accuracy in determining tumor positive vs tumor negative
Daisy, a 10-year-old Labrador at the time, was awarded the prestigious Blue Cross Medal in 2014 for her pioneering work in cancer
Dr. Martinov begins solving complex discovery problems using Machine Learning for Pharma
